If you have been reading about lyophilisation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-23. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
Reversed-phase high-performance liquid chromatography is the routine method for purity assessment. Peptides absorb near 214 nm because of the peptide bond, and a gradient of acetonitrile in water separates the intact peptide from deletion sequences, oxidised products, and earlier-eluting fragments at neutral pH. Electrospray ionisation mass spectrometry provides an orthogonal check: the measured mass must agree with the theoretical value. Amino acid analysis and peptide mapping confirm structure but are used less often. Reference standards remain scarce because the peptide is not described in any pharmacopoeia.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Alpha-MSH analogue with a lactam ring |
| Molecular formula | C50H69N15O9 | Commonly cited value for the neutral peptide |
| Molecular weight | 1024.18 g/mol | Calculated for the free molecule |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water, DMSO and ethanol | Dissolution in pure water is often slow |
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
In late 2012, a yellow fever outbreak occurred in the Darfur region of Sudan that was the largest yellow fever epidemic to strike Africa in two decades. On 10 January 2013, the Sudan Federal Ministry of Health and the World Health Organization (WHO) reported that there had been 847 suspected cases since 2 September 2012, including 171 deaths, for an estimated case fatality rate of 20%. A mass vaccination campaign was launched in mid-November. By early January, the five states of Darfur were free of any new cases.
The New World connections were conflated, the plant being misattributed to Brazil, resulting in the name toupinambeaux (earliest known use 1618) being applied to the tubers in French. By 1658, topinambour is found. From there, the word made its way into other European languages.
=== 2000-present === In 2000, the company opened a central laboratory in Singapore, building on clinical-development services formed in Singapore in 1996. In 2013, it expanded the capacity of the laboratory by 50%. In March 2001, the company sold Covance Pharmaceutical Packaging Services to Fisher Scientific for $137.5 million. In August 2005, it acquired GFI Clinical Services, an 80-bed clinical pharmacology business, from West Pharmaceutical Services for $5.7 million. In April 2006, the company acquired eight early phase clinical pharmacology sites from Radiant Research for $65 million. In June 2006, it acquired Signet Laboratories, a provider of monoclonal antibodies used in the research of cancer, infectious disease, and neurodegenerative disease, for $8.95 million. In 2007, the company opened a laboratory in Shanghai, China. In 2019, it opened a research and development center in Shanghai. In August 2008, the company acquired a campus in Greenfield, Indiana from Eli Lilly and Company and executed a 10-year service drug development service agreement with Lilly. In December 2008, the company acquired a minority equity stake in Caprion Proteomics, a provider of proteomics-based services to the pharmaceutical industry. The company was acquired by Chicago Growth Partners in July 2012. In 2009, the company acquired the Gene Expression Laboratory from Merck & Co. and entered into a five-year, $145 million contract to provide Merck with genomic analysis services.
== Security cooperation == The agreement aligns with simultaneous U.S.–Pakistan counterterrorism collaboration: the U.S. designated the Balochistan Liberation Army (BLA) as a terrorist organization, a move lauded by Karachi and carried out amid discussions surrounding the trade accord.
Sources: en.wikipedia.org
chromocenter A central amorphous mass of polytene chromosomes found in the nuclei of cells of the salivary glands in Drosophila larvae and resulting from the fusion of heterochromatic regions surrounding the centromeres of the somatically paired chromosomes, with the distal euchromatic arms radiating outward.
== 21st century == The Progressive Alliance is a political international organisation founded on 22 May 2013 by left-wing political parties, the majority of which are current or former members of the Socialist International. The organisation states that its aim is becoming the global network of "the progressive, democratic, social-democratic, socialist and labour movement." On 30 November 2018, The Sanders Institute and the Democracy in Europe Movement 2025 founded the Progressive International, an international political organisation which unites democratic socialists with labour unionists, progressives and social democrats.
Hospital medicine is the general medical care of hospitalized patients. Physicians whose primary professional focus is hospital medicine are called hospitalists in the United States and Canada. The term Most Responsible Physician (MRP) or attending physician is also used interchangeably to describe this role. Laser medicine involves the use of lasers in the diagnostics or treatment of various conditions. Many other health science fields, e.g. dietetics Medical ethics deals with ethical and moral principles that apply values and judgments to the practice of medicine. Medical humanities includes the humanities (literature, philosophy, ethics, history and religion), social science (anthropology, cultural studies, psychology, sociology), and the arts (literature, theater, film, and visual arts) and their application to medical education and practice. Nosokinetics is the science/subject of measuring and modelling the process of care in health and social care systems. Nosology is the classification of diseases for various purposes. Occupational medicine is the provision of health advice to organizations and individuals to ensure that the highest standards of health and safety at work can be achieved and maintained. Pain management (also called pain medicine, or algiatry) is the medical discipline concerned with the relief of pain. Pharmacogenomics is a form of individualized medicine. Podiatric medicine is the study of, diagnosis, and medical treatment of disorders of the foot, ankle, lower limb, hip and lower back.
==== Flowering ==== Blooms occur when the day length becomes shorter than 12 hours (beginning in mid-October in some places), necessitating the use of shade cloth in urban environments with exposure to light pollution caused by HPS lighting. Both Siebert and hobbyist reports indicate that viable seeds can, on occasion, be produced under cultivation, following hand-pollination or hummingbird pollination.
consistent, clinically established pharmacodynamic relationships between plasma drug concentrations and pharmacological efficacy and/or toxicity; significant between-patient pharmacokinetic variability, making a standard dosage achieve different concentration levels among patients (while the drug disposition remains relatively stable in a given patient); narrow therapeutic window of the drug, which forbids giving high doses in all patients to ensure overall efficacy; drug dosage optimization not achievable based on clinical observation alone; duration of the treatment and criticality for patient's condition justifying dosage adjustment efforts; potential patient compliance problems that might be remedied through concentration monitoring. TDM determinations are also used to detect and diagnose poisoning with drugs, should the suspicion arise. Examples of drugs widely analysed for therapeutic drug monitoring:
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.
No national medicines agency has approved melanotan-2 for clinical use. Afamelanotide, a related but distinct peptide, holds a marketing authorisation in the European Union for a rare photosensitivity disorder. Melanotan-2 itself is handled as a laboratory chemical.
Its broad activity across melanocortin receptors makes it a tool for probing pigmentation, appetite and vascular signalling. Early trials recorded skin darkening and other effects that were not the original focus of the work. Those observations generated hypotheses that later studies have examined.
Low temperature slows hydrolysis and oxidation, the two main routes by which the peptide backbone and side chains are modified. A lyophilised powder stored at −20 °C is more stable than one kept at room temperature, and once the material is dissolved the degradation rate rises, making refrigeration more important.